Nervous system disease

RetinalGeniX Technologies, Inc. Acquires DNA/GPS Inc.

Retrieved on: 
Wednesday, July 6, 2022
Diagnosis, Deep learning, Acquisition, OTCQB, Science, Patient, Dementia, Systemic disease, Nervous system disease, Severe cognitive impairment, Pharmacogenomics, GLOBE, Intelligence, Laboratory, Retina, Disease, Parkinson's disease, CT, PET, Technology, Private Securities Litigation Reform Act, SEC, Risk, Degenerative disease, Hospital, Kidney disease, Alzheimer's disease, Eye, MRI, Medical device, Medical imaging, MD

PETALUMA, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies, Inc. (OTCQB:RTGN) (RetinalGeniX or the Company),announced today the acquisition of DNA/GPS Inc., apharmacogenetics company based in Tampa, Florida and foundedby Dr. Larry Perich.

Key Points: 
  • PETALUMA, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies, Inc. (OTCQB:RTGN) (RetinalGeniX or the Company),announced today the acquisition of DNA/GPS Inc., apharmacogenetics company based in Tampa, Florida and foundedby Dr. Larry Perich.
  • The new platform is being designed to enable us to determine the right patients to screen and should assist healthcare providers to choose the most effective early interventions.
  • With the guidance of RetinalGeniX DNA/GPS, the company intends to focus on patients that have genetic predisposition to multiple systemic diseases.
  • This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study

Retrieved on: 
Friday, May 14, 2021
Branches of biology, Membrane biology, Liposome, Ramot at Tel Aviv University, Ramot, Jerusalem, Nervous system disease, Central nervous system disease, Biology

This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders.

Key Points: 
  • This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders.
  • Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Coronavirus using CBD.
  • Innocan Israel plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications.
  • The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.\n'

Global Central Nervous System Partnering Deals Directory 2014-2020: Access to Headline, Upfront, Milestone and Royalty Data

Retrieved on: 
Wednesday, March 24, 2021
Neurology, Nervous system disease

The Global Central Nervous System Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 1,400 central nervous system deals.

Key Points: 
  • The Global Central Nervous System Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 1,400 central nervous system deals.
  • The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.
  • In addition, a comprehensive appendix is provided with each report of all Central Nervous System partnering deals signed and announced since 2014.
  • Global Central Nervous System Partnering 2014 to 2020 includes:
    In Global Central Nervous System Partnering 2014 to 2020, available deals and contracts are listed by:

Global Central Nervous System Partnering Directory 2014-2020: Deal Trends, Players and Financials Analysis of 1,400 Deal Records - ResearchAndMarkets.com

Retrieved on: 
Monday, March 22, 2021
Health, Pharmaceutical, Neurology, Nervous system disease

The "Global Central Nervous System Partnering 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Central Nervous System Partnering 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Central Nervous System Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 1,400 central nervous system deals.
  • The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.
  • Global Central Nervous System Partnering 2014 to 2020 includes:
    In Global Central Nervous System Partnering 2014 to 2020, available deals and contracts are listed by:

Worldwide Industry for Neurologic Condition Genetic Testing to 2025 - Featuring Ambry Genetics, Arup Laboratories & Asuragen Among Others

Retrieved on: 
Tuesday, February 16, 2021
Branches of biology, Biology, Medical specialties, Psychiatric diagnosis, Medical genetics, Neurological disorders, Neurology, Autism, Central nervous system disease, Genetic testing, Nervous system disease, Alzheimer's disease

Central nervous system disorders account for approximately 60 percent of the 6,400 phenotypic entries in cataloged inherited human diseases.

Key Points: 
  • Central nervous system disorders account for approximately 60 percent of the 6,400 phenotypic entries in cataloged inherited human diseases.
  • Increasing awareness of neurological disorders, the aging population, and continued advancements in medical genetics will likely drive the neurological genetic testing market.
  • This report Genetic Testing Markets for Epilepsy, Autism, Alzheimer's and Other Neurologic Conditions focuses on the neurological segments of the inherited/ genetic disease testing market, including autism, Alzheimer's disease and other neurological diseases.
  • As part of its coverage, this report provides:
    Genetic Testing by Disease Type (Autism, Alzheimer's and other Neurological Diseases) 2020-2025 (in $ millions)

Central Nervous System Disorders Therapeutics Market to Showcase Positive Growth During 2020-2024 | Technavio

Retrieved on: 
Thursday, November 19, 2020
Health, Pharmaceutical, Business process, Market analysis, Market research, Nervous system disease

View the full release here: https://www.businesswire.com/news/home/20201119005908/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20201119005908/en/
    Technavio has announced its latest market research report titled Global Central Nervous System Disorders Therapeutics Market 2020-2024 (Graphic: Business Wire)
    The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment facing direct and indirect COVID-19 impact.
  • To learn more about the global trends impacting the future of market research, download a free sample now
    The market is fragmented due to the presence of central nervous system disorders therapeutics manufacturing companies.
  • To help clients improve their market position, this central nervous system disorders therapeutics market forecast report provides a detailed analysis of the market leaders.
  • Moreover, this central nervous system disorders therapeutics market analysis report also provides information on the upcoming trends and challenges that will influence market growth.

Praxis Precision Medicines Expands Leadership Team to Advance its Pipeline for CNS Disorders

Retrieved on: 
Thursday, September 17, 2020
Biotechnology, Mental health, Health, Genetics, Pharmaceutical, Neurology, Central nervous system disease, Nervous system disease

Mr. Mitchell replaces former chairman Nicholas Galakatos, Ph.D., global head of Blackstone Life Sciences, who will continue to serve as a director of Praxis.

Key Points: 
  • Mr. Mitchell replaces former chairman Nicholas Galakatos, Ph.D., global head of Blackstone Life Sciences, who will continue to serve as a director of Praxis.
  • Praxis is at an exciting stage in its evolution following our recent financing, with multiple potential value creating milestones expected over the next year.
  • Praxis is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance.
  • We have established a broad portfolio, including five disclosed programs across multiple CNS disorders, including depression, epilepsy, movement disorders and pain syndromes.

2020 Global Central Nervous System Disorders Pipeline Database - ResearchAndMarkets.com

Retrieved on: 
Friday, May 29, 2020
Health, Pharmaceutical, Organ systems, Branches of biology, Nervous system, Central nervous system disease, Nervous system disease, Neurotransmitters, Clinical neuroscience, ICD-10 Chapter VI: Diseases of the nervous system

The "Central Nervous System Disorders Pipeline Database - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Central Nervous System Disorders Pipeline Database - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This database provides the most up-to-date information on key pipeline products in the global Central Nervous System (CNS) disorders drug market.
  • Key indications covered in this database include Multiple Sclerosis, Depression, Alzheimer's disease, Parkinson's disease, ADHD, Schizophrenia, Epilepsy, Migraine, and Huntington's disease.
  • The database provides CNS disorders pipeline products by their dominant drug mechanism class.

2020 Insights into the Worldwide Central Nervous System Partnering - Trends in Partnering Deals Since 2014 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 8, 2020
Biotechnology, General Health, Pharmaceutical, Health, Nervous system disease, Neurology, Pharmaceutical industry

The "Global Central Nervous System Partnering 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Central Nervous System Partnering 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.
  • Global Central Nervous System Partnering 2014 to 2020 provides the full collection of Central Nervous System disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
  • Global Central Nervous System Partnering 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Central Nervous System trends and structure of deals entered into by leading companies worldwide.

Drug Delivery in Central Nervous System (CNS) Diseases - Global Markets to 2028 Featuring 75 Company Profiles & 101 Collaborations

Retrieved on: 
Tuesday, September 17, 2019
Neurology, Nervous system disease, Neuroscience, Nanoparticles for drug delivery to the brain, Biovista

Dublin, Sept. 17, 2019 (GLOBE NEWSWIRE) -- The "Drug Delivery in Central Nervous System Diseases - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Dublin, Sept. 17, 2019 (GLOBE NEWSWIRE) -- The "Drug Delivery in Central Nervous System Diseases - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders.
  • Advances in understanding of the cell biology of the BBB have opened new avenues and possibilities for improved drug delivery to the CNS.
  • Profiles of 75 companies involved in drug delivery for CNS disorders are presented along with their technologies, products and 101 collaborations.